Regeneron revenue beats estimates on strong sales of Eylea, COVID therapy
-Regeneron Pharmaceuticals Inc on Friday reported fourth-quarter revenue that beat analysts’ estimates, boosted by demand for blockbuster drugs Dupixent and Eylea, coupled with higher sales of its COVID-19 therapy. Sales…